April 17, 2024 News by Steve Bryson, PhD NfL blood levels predict CIS to MS conversion: Clinical trial data High blood levels of the nerve damage biomarker neurofilament light chain (NfL) significantly increased the risk of people with clinically isolated syndrome (CIS) converting to definite multiple sclerosis (MS), according to an analysis of clinical trial data. CIS patients with higher NfL levels also made the transition earlier…
October 17, 2023 News by Marisa Wexler, MS ECTRIMS 2023: Blood biomarker may help to predict disability in MS Blood levels of neurofilament light chain (NfL), a marker of nerve damage, were seen to increase about a year or two prior to disability worsening in people with multiple sclerosis (MS), particularly among patients whose disease progressed without any relapse activity. That’s according to new data presented at the…
July 12, 2023 News by Steve Bryson, PhD NfL blood levels may help predict long-term progression of MS: Study Elevated blood levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with long-term disability progression in people with multiple sclerosis (MS) ā even among those without acute relapses or MRI disease activity ā a study revealed. The results demonstrate the potential utility of NfL blood…
March 31, 2023 News by Andrea Lobo, PhD Fujirebio launched 2 automated tests to quantify key protein in blood, CSF Fujirebio has launched two fully automated laboratory tests to measure levels of the neurofilament light chain (NfL) protein, a proposed biomarker of nerve cell damage in multiple sclerosis (MS), in the blood and spinal fluid. NfL is a structural protein found in nerve cells that gets released into…
February 2, 2023 News by Margarida Maia, PhD Aubagio Significantly Lowers Plasma NfL Levels in TERIKIDS Trial Aubagio (teriflunomide) can significantly reduce plasma neurofilament light chain (pNfL) levels, a biomarker of nerve cell damage, in children and adolescents with relapsing-remitting multiple sclerosis (RRMS). Thatās according to a new analysis of data from TERIKIDS (NCT02201108), the Phase 3 trial that supported expanding Aubagio’s indication in…
July 5, 2022 News by Steve Bryson, PhD Estriol Plus Copaxone May Protect Against Nerve Damage in RRMS Taking the pregnancy hormone estriol in combination with Copaxone (glatiramer acetate) significantly reduced the blood levels of neurofilament light chain (NfL) ā a marker of nerve damage ā in women with relapsing-remitting multiple sclerosis (RRMS), clinical trial data show. These lower NfL levels were significantly associated with a…
April 28, 2022 News by Lindsey Shapiro, PhD Blood Biomarker Test Granted Breakthrough Device Status by FDA Quanterixās ultra-sensitive blood test that measures a biomarker of nerve damage in people with multiple sclerosis (MS) has been granted a breakthrough device designation by U.S. regulators. It is thought that the test, which employs the companyās Simoa technology, can accurately predict the risk of disease activity in…
April 25, 2022 News by Lindsey Shapiro, PhD In Relapsing MS, NfL Levels Help in Disease Progression Prediction Serum levels of neurofilament light chain (NfL) ā proteins found in nerve cell projections ā can help in the prediction of disease progression among people with relapsing forms of multiple sclerosis (MS), according to an analysis of data from two large Phase 3 trials. The researchers said that NfL…
March 7, 2022 News by Marta Figueiredo, PhD Stem Cell Therapy NG-01 Shows Neuroprotective Effects in Trial Administering the stem cell therapy NG-01 ā designed to have neuroprotective and neuro-regenerative properties ā directly into the spinal canal can significantly reduce the levels of neurofilament light chain (NfL), a neuronal damage biomarker, in people with active, progressive forms of multiple sclerosis (MS). These are the new…